146
Views
18
CrossRef citations to date
0
Altmetric
Drug profile

PTH(1-84) replacement therapy for the treatment of hypoparathyroidism

, &
Pages 5-13 | Published online: 28 Oct 2014
 

Abstract

Hypoparathyroidism is a rare disease characterized by hypocalcemia and insufficient circulating levels of parathyroid hormone (PTH). Conventional therapy includes calcium and active vitamin D supplementation, often in large doses. Therapy with calcium and vitamin D, however, does not address certain problematic aspects of the disease, including abnormal bone metabolism and reduced quality of life. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. PTH(1-84) may soon become a therapeutic option for patients with hypoparathyroidism. PTH(1-84) has been demonstrated to maintain serum calcium while reducing or eliminating requirements for calcium and active vitamin D supplementation. Data from bone densitometry, bone turnover markers and histomorphometry of bone biopsy specimens show positive structural and dynamic effects on the skeleton. PTH replacement therapy may also be associated with improved quality of life. PTH(1-84) replacement therapy for hypoparathyroidism is promising, although further acquisition of long-term data is needed.

Financial & competing interests disclosure

The authors would like to acknowledge the following funding sources: National Institutes of Health grants DK069350 and DK095944 and Food and Drug Administration grant 002525. MR Rubin receives research support from NPS Pharmaceuticals. JP Bilezikian is a consultant for Eli Lilly, NPS Pharmaceuticals, Merck and Amgen and receives research support from NPS Pharmaceuticals and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Key issues
  • Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, parathyroid hormone (PTH), is not yet an approved treatment.

  • PTH(1-84) is a promising therapeutic option for patients with hypoparathyroidism.

  • PTH(1-84) therapy has been demonstrated to decrease calcium and active vitamin D requirements while maintaining serum calcium and to improve the abnormal bone remodeling state in subjects with hypoparathyroidism.

  • Given the chronic nature of the disease and the need for ongoing PTH therapy, further long-term data are necessary.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 608.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.